

# **MDGs Achievement and New Challenges and Opportunities**

## **Intellectual Property and Trade issues related to public health**

**Manisha Shridhar PhD**  
**Intellectual Property Rights and Trade and Health,**  
**WHO-SEARO email:shridharm@searo.who.int**

# Current Scenario in IP and Trade issues in Public Health

- AIDS to HIV 1998 Africa-chronic disease
- Doha Round in WTO, Para 6
- TRIPS flexibilities
- Changing financial commitments
- CDs/NCDs blurring
- Challenge of FTAs
- WHO Framework Convention on Tobacco Control (FCTC) and the relationship with trade agreements- plain packaging and WTO
- Pharmaceutical chains drying up SPC/Mergers and acquisitions

# WHO Response

## GSPA on public health, innovation and intellectual property (WHA61.21)

- GSPA (2008)-IGWG pursuant to the independent Commission on Intellectual Property Rights (IPR), Innovation and Public Health (CIPIH) under WHA56.27 in 2003.
- The CIPIH report (2006 )-status of innovation, IPR and the pharmaceutical industry
- 108 specific actions across 25 sub elements and eight main elements. These main elements are:
  1. prioritizing research and development needs;
  2. promoting research and development;
  3. building and improving innovative capacity;
  4. transfer of technology;
  5. application and management of intellectual property to contribute to innovation and promote public health;
  6. improving delivery and access;
  7. promoting sustainable financing mechanisms; and
  8. establishing and monitoring reporting systems.

# **CEWG on Research and Development: financing and coordination for public health, innovation and intellectual property**

- Consultative Expert Working Group (CEWG) on Research and Development: financing and coordination
- The proposals found to be accomplishing the relevant criteria are:
  - A globally binding R&D instrument
  - Direct grants to companies in developing countries
  - Equitable licensing
  - Patent pools,
  - Pooled funds,
  - Precompetitive R&D platforms/Open source and access and
  - Prizes

# South East-Asia Regional Response

- Regional Resolutions **SEA/RC62/R6, 2009** and **SEA/RC63/R6, 2010** - capacity building to implement trade and intellectual property policies for access to safe, efficacious, quality and affordable medical products
- A Regional Consultation for “**Regional Framework on Public Health, Innovation and Intellectual Property**” was held in WHO-SEARO, New Delhi, on 5-6 April 2011 that has identified national and regional priorities for all eight elements and 25 sub-elements of GSPA on a set of templates.
- Regional Meeting was held on Consultative Expert Working Group (CEWG) progress for Member States representatives in SEARO on 7 October 2011.

# Pharmaceutical MSMEs based on investment in machinery (size of enterprises) and products

Investment Sector →	Micro	Small	Others	Total
Pharmaceutical & Medical products	1 485	568	205	2 258
Pharmaceutical products	11 254	374	130	11 758
Pharmaceutical machinery	422	27	7	456
Pharmaceutical products and machinery	1 497	114	76	1 687
Pharmaceutical sector	14 658	1 083	418	16 159

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_7769](https://www.yunbaogao.cn/report/index/report?reportId=5_7769)

